Marktanalyse - Prostate Cancer - Pipeline Review, H2 2016

Global Markets Direct
12.2016
1699 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Prostate Cancer - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer — Pipeline Review, H2 2016, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 91, 98, 4, 231, 32 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 10, 58 and 23 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 14

Prostate Cancer Overview 15

Therapeutics Development 16

Prostate Cancer - Therapeutics under Development by Companies 18

Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 41

Prostate Cancer - Pipeline Products Glance 46

Prostate Cancer - Products under Development by Companies 50

Prostate Cancer - Products under Investigation by Universities/Institutes 82

Prostate Cancer - Companies Involved in Therapeutics Development 89

Prostate Cancer - Therapeutics Assessment 370

Drug Profiles 404

Prostate Cancer - Dormant Projects 1571

Prostate Cancer - Discontinued Products 1619

Prostate Cancer - Product Development Milestones 1629

Appendix 1639





List of Tables

Number of Products under Development for Prostate Cancer, H2 2016 75

Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2016 76

Number of Products under Development by Companies, H2 2016 77

Number of Products under Development by Companies, H2 2016 (Contd..1) 78

Number of Products under Development by Companies, H2 2016 (Contd..2) 79

Number of Products under Development by Companies, H2 2016 (Contd..3) 80

Number of Products under Development by Companies, H2 2016 (Contd..4) 81

Number of Products under Development by Companies, H2 2016 (Contd..5) 82

Number of Products under Development by Companies, H2 2016 (Contd..6) 83

Number of Products under Development by Companies, H2 2016 (Contd..7) 84

Number of Products under Development by Companies, H2 2016 (Contd..8) 85

Number of Products under Development by Companies, H2 2016 (Contd..9) 86

Number of Products under Development by Companies, H2 2016 (Contd..10) 87

Number of Products under Development by Companies, H2 2016 (Contd..11) 88

Number of Products under Development by Companies, H2 2016 (Contd..12) 89

Number of Products under Development by Companies, H2 2016 (Contd..13) 90

Number of Products under Development by Companies, H2 2016 (Contd..14) 91

Number of Products under Development by Companies, H2 2016 (Contd..15) 92

Number of Products under Development by Companies, H2 2016 (Contd..16) 93

Number of Products under Development by Companies, H2 2016 (Contd..17) 94

Number of Products under Development by Companies, H2 2016 (Contd..18) 95

Number of Products under Development by Companies, H2 2016 (Contd..19) 96

Number of Products under Development by Companies, H2 2016 (Contd..20) 97

Number of Products under Development by Companies, H2 2016 (Contd..21) 98

Number of Products under Development by Companies, H2 2016 (Contd..22) 99

Number of Products under Investigation by Universities/Institutes, H2 2016 100

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 101

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 102

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 103

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 104

Comparative Analysis by Late Stage Development, H2 2016 105

Comparative Analysis by Clinical Stage Development, H2 2016 106

Comparative Analysis by Early Stage Development, H2 2016 107

Comparative Analysis by Unknown Stage Development, H2 2016 108

Products under Development by Companies, H2 2016 109

Products under Development by Companies, H2 2016 (Contd..1) 110

Products under Development by Companies, H2 2016 (Contd..2) 111

Products under Development by Companies, H2 2016 (Contd..3) 112

Products under Development by Companies, H2 2016 (Contd..4) 113

Products under Development by Companies, H2 2016 (Contd..5) 114

Products under Development by Companies, H2 2016 (Contd..6) 115

Products under Development by Companies, H2 2016 (Contd..7) 116

Products under Development by Companies, H2 2016 (Contd..8) 117

Products under Development by Companies, H2 2016 (Contd..9) 118

Products under Development by Companies, H2 2016 (Contd..10) 119

Products under Development by Companies, H2 2016 (Contd..11) 120

Products under Development by Companies, H2 2016 (Contd..12) 121

Products under Development by Companies, H2 2016 (Contd..13) 122

Products under Development by Companies, H2 2016 (Contd..14) 123

Products under Development by Companies, H2 2016 (Contd..15) 124

Products under Development by Companies, H2 2016 (Contd..16) 125

Products under Development by Companies, H2 2016 (Contd..17) 126

Products under Development by Companies, H2 2016 (Contd..18) 127

Products under Development by Companies, H2 2016 (Contd..19) 128

Products under Development by Companies, H2 2016 (Contd..20) 129

Products under Development by Companies, H2 2016 (Contd..21) 130

Products under Development by Companies, H2 2016 (Contd..22) 131

Products under Development by Companies, H2 2016 (Contd..23) 132

Products under Development by Companies, H2 2016 (Contd..24) 133

Products under Development by Companies, H2 2016 (Contd..25) 134

Products under Development by Companies, H2 2016 (Contd..26) 135

Products under Development by Companies, H2 2016 (Contd..27) 136

Products under Development by Companies, H2 2016 (Contd..28) 137

Products under Development by Companies, H2 2016 (Contd..29) 138

Products under Development by Companies, H2 2016 (Contd..30) 139

Products under Development by Companies, H2 2016 (Contd..31) 140

Products under Investigation by Universities/Institutes, H2 2016 141

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 142

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 143

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 144

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 145

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 146

Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 147

Prostate Cancer - Pipeline by 4SC AG, H2 2016 148

Prostate Cancer - Pipeline by AB Science SA, H2 2016 149

Prostate Cancer - Pipeline by AbbVie Inc, H2 2016 150

Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 151

Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 152

Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016 153

Prostate Cancer - Pipeline by Addex Therapeutics Ltd, H2 2016 154

Prostate Cancer - Pipeline by Aduro BioTech Inc, H2 2016 155

Prostate Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016 156

Prostate Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 157

Prostate Cancer - Pipeline by Advantagene Inc, H2 2016 158

Prostate Cancer - Pipeline by Advaxis Inc, H2 2016 159

Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 160

Prostate Cancer - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016 161

Prostate Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016 162

Prostate Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016 163

Prostate Cancer - Pipeline by Akshaya Bio Inc, H2 2016 164

Prostate Cancer - Pipeline by Alchemia Ltd, H2 2016 165

Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016 166

Prostate Cancer - Pipeline by Alissa Pharma, H2 2016 167

Prostate Cancer - Pipeline by Almac Discovery Ltd, H2 2016 168

Prostate Cancer - Pipeline by Ambrx Inc, H2 2016 169

Prostate Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 170

Prostate Cancer - Pipeline by Amgen Inc, H2 2016 171

Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 172

Prostate Cancer - Pipeline by AndroScience Corp, H2 2016 173

Prostate Cancer - Pipeline by AnGes MG Inc, H2 2016 174

Prostate Cancer - Pipeline by AntiCancer Inc, H2 2016 175

Prostate Cancer - Pipeline by Antigen Express Inc, H2 2016 176

Prostate Cancer - Pipeline by Antisense Therapeutics Ltd, H2 2016 177

Prostate Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016 178

Prostate Cancer - Pipeline by Apcure SAS, H2 2016 179

Prostate Cancer - Pipeline by Aphios Corp, H2 2016 180

Prostate Cancer - Pipeline by APIM Therapeutics AS, H2 2016 181

Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 182

Prostate Cancer - Pipeline by Aptose Biosciences Inc, H2 2016 183

Prostate Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 184

Prostate Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 185

Prostate Cancer - Pipeline by Arno Therapeutics Inc, H2 2016 186

Prostate Cancer - Pipeline by ArQule Inc, H2 2016 187

Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 188

Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 189

Prostate Cancer - Pipeline by Arvinas Inc, H2 2016 190

Prostate Cancer - Pipeline by Asana BioSciences LLC, H2 2016 191

Prostate Cancer - Pipeline by Astellas Pharma Inc, H2 2016 192

Prostate Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2016 193

Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2016 194

Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 195

Prostate Cancer - Pipeline by Aura Biosciences Inc, H2 2016 196

Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 197

Prostate Cancer - Pipeline by Avipep Pty Ltd, H2 2016 198

Prostate Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 199

Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 200

Prostate Cancer - Pipeline by Bayer AG, H2 2016 201

Prostate Cancer - Pipeline by BeiGene Ltd, H2 2016 202

Prostate Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 203

Prostate Cancer - Pipeline by BHR Pharma LLC, H2 2016 204

Prostate Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 205

Prostate Cancer - Pipeline by Biotest AG, H2 2016 206

Prostate Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016 207

Prostate Cancer - Pipeline by Blirt SA, H2 2016 208

Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 209

Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 210

Prostate Cancer - Pipeline by Camurus AB, H2 2016 211

Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016 212

Prostate Cancer - Pipeline by CEL-SCI Corp, H2 2016 213

Prostate Cancer - Pipeline by Celgene Corp, H2 2016 214

Prostate Cancer - Pipeline by CellCentric Ltd, H2 2016 215

Prostate Cancer - Pipeline by Cellceutix Corp, H2 2016 216

Prostate Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 217

Prostate Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 218

Prostate Cancer - Pipeline by Cellmid Ltd, H2 2016 219

Prostate Cancer - Pipeline by Celprogen Inc, H2 2016 220

Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H2 2016 221

Prostate Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 222

Prostate Cancer - Pipeline by Clovis Oncology Inc, H2 2016 223

Prostate Cancer - Pipeline by CohBar Inc, H2 2016 224

Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H2 2016 225

Prostate Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016 226

Prostate Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 227

Prostate Cancer - Pipeline by Crescendo Biologics Ltd, H2 2016 228

Prostate Cancer - Pipeline by Curevac AG, H2 2016 229

Prostate Cancer - Pipeline by CytoVac A/S, H2 2016 230

Prostate Cancer - Pipeline by CZ BioMed Corp, H2 2016 231

Prostate Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 232

Prostate Cancer - Pipeline by DEKK-TEC Inc, H2 2016 233

Prostate Cancer - Pipeline by DexTech Medical AB, H2 2016 234

Prostate Cancer - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 235

Prostate Cancer - Pipeline by DNJ Pharma Inc, H2 2016 236

Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2016 237

Prostate Cancer - Pipeline by DormaTarg Inc, H2 2016 238

Prostate Cancer - Pipeline by Eisai Co Ltd, H2 2016 239

Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2016 240

Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2016 241

Prostate Cancer - Pipeline by EndoCeutics Inc, H2 2016 242

Prostate Cancer - Pipeline by Endocyte Inc, H2 2016 243

Prostate Cancer - Pipeline by EntreChem SL, H2 2016 244

Prostate Cancer - Pipeline by EOS Biosciences Inc, H2 2016 245

Prostate Cancer - Pipeline by Errant Gene Therapeutics LLC, H2 2016 246

Prostate Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2016 247

Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2016 248

Prostate Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016 249

Prostate Cancer - Pipeline by Evgen Pharma Plc, H2 2016 250

Prostate Cancer - Pipeline by Exonate Ltd, H2 2016 251

Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 252

Prostate Cancer - Pipeline by Ferring International Center SA, H2 2016 253

Prostate Cancer - Pipeline by Foresee Pharmaceuticals LLC, H2 2016 254

Prostate Cancer - Pipeline by Fountain Biopharma Inc, H2 2016 255

Prostate Cancer - Pipeline by Fujifilm Corp, H2 2016 256

Prostate Cancer - Pipeline by G1 Therapeutics Inc, H2 2016 257

Prostate Cancer - Pipeline by Galectin Therapeutics Inc, H2 2016 258

Prostate Cancer - Pipeline by Genelux Corp, H2 2016 259

Prostate Cancer - Pipeline by Genentech Inc, H2 2016 260

Prostate Cancer - Pipeline by GeneSegues Inc, H2 2016 261

Prostate Cancer - Pipeline by Genmab A/S, H2 2016 262

Prostate Cancer - Pipeline by Gilead Sciences Inc, H2 2016 263

Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2016 264

Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 265

Prostate Cancer - Pipeline by GlycoMimetics Inc, H2 2016 266

Prostate Cancer - Pipeline by GP Pharm SA, H2 2016 267

Prostate Cancer - Pipeline by GTx Inc, H2 2016 268

Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 269

Prostate Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 270

Prostate Cancer - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2016 271

Prostate Cancer - Pipeline by Hybrigenics SA, H2 2016 272

Prostate Cancer - Pipeline by IC-MedTech Inc, H2 2016 273

Prostate Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016 274

Prostate Cancer - Pipeline by IGF Oncology LLC, H2 2016 275

Prostate Cancer - Pipeline by Ignyta Inc, H2 2016 276

Prostate Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2016 277

Prostate Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016 278

Prostate Cancer - Pipeline by Immuneed AB, H2 2016 279

Prostate Cancer - Pipeline by Immunocore Ltd, H2 2016 280

Prostate Cancer - Pipeline by ImmunoFrontier Inc, H2 2016 281

Prostate Cancer - Pipeline by Immunomedics Inc, H2 2016 282

Prostate Cancer - Pipeline by Immupharma Plc, H2 2016 283

Prostate Cancer - Pipeline by Incanthera Ltd, H2 2016 284

Prostate Cancer - Pipeline by Incuron LLC, H2 2016 285

Prostate Cancer - Pipeline by Inflection Biosciences Ltd, H2 2016 286

Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 287





List of Figures

Number of Products under Development for Prostate Cancer, H2 2016 75

Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2016 76

Number of Products under Development by Companies, H2 2016 77

Number of Products under Investigation by Universities/Institutes, H2 2016 100

Comparative Analysis by Late Stage Development, H2 2016 105

Comparative Analysis by Clinical Stage Development, H2 2016 106

Comparative Analysis by Early Stage Products, H2 2016 107

Assessment by Monotherapy Products, H2 2016 429

Assessment by Combination Products, H2 2016 430

Number of Products by Top 10 Targets, H2 2016 431

Number of Products by Stage and Top 10 Targets, H2 2016 431

Number of Products by Top 10 Mechanism of Actions, H2 2016 445

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 445

Number of Products by Top 10 Routes of Administration, H2 2016 459

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 459

Number of Products by Top 10 Molecule Types, H2 2016 461

Number of Products by Stage and Top 10 Molecule Types, H2 2016 461

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus